07/12/2018 02:15:15

Synthorx Announces Pricing of Initial Public Offering

SAN DIEGO, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the pricing of its initial public offering of 11,912,727 shares of common stock at a public offering price of $11.00 per share.  Synthorx anticipates total gross proceeds of approximately $131 million, before deducting underwriting discounts and commissions and other offering expenses. All shares of common stock are being offered by Synthorx. The shares are expected to begin trading on The Nasdaq Global Select Market on December 7, 2018 under the ticker symbol "THOR." The offering is expected to close on or about December 11, 2018, subject to customary closing conditions. In addition, Synthorx has granted the underwriters a 30-day option to purchase up to an additional 1,786,909 shares of common stock at the initial public offering price.

Jefferies LLC, Leerink Partners LLC and Evercore ISI are acting as joint book-running managers for the offering. H.C. Wainwright & Co., LLC is acting as lead manager for the offering.

Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on December 6, 2018. The offering will be made only by means of a prospectus. Copies of the final prospectus relating to the offering, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022 or by telephone at (877) 547-6340 or by email at Prospectus_Department@Jefferies.com; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 or by telephone at (800) 808-7525, ext. 6132 or by email at syndicate@leerink.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, New York, NY 10055 or by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Synthorx

Synthorx, Inc. is a biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Synthorx’s proprietary, first-of-its-kind Expanded Genetic Alphabet platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, referred to as Synthorins. A Synthorin is a protein optimized through incorporation of novel amino acids encoded by the new DNA base pair that enables site-specific modifications, which enhance the pharmacological properties of these therapeutics. The company’s lead product candidate, THOR-707, a variant of IL-2, is in development in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded based on important discoveries in Dr. Floyd Romesberg’s lab at The Scripps Research Institute. The company is headquartered in La Jolla, Calif.

Corporate Development/IR Contact:

Enoch Kariuki, Pharm.D.

Synthorx, Inc.

ekariuki@synthorx.com

858-750-4750

Media Relations Contact

Lauren Fish

Canale Communications

lauren@canalecomm.com

619-849-5386

synthorx_logo_color_600dpi.png

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
17 Feb
VWS
  Jeg har nu haft lidt tid til at læse det seneste årsregnskab fra Vestas. Jeg har forsøgt at opsumm..
62
21 Feb
VELO
Især 2 ting har fanget min opmærksomhed i de seneste døgn. 1) Astellas er udtrådt af AST )American S..
22
15 Feb
VELO
Jeg kan se på FB-gruppen at er der en diskussion omkring præparatet fra Hansa Medical det evt. ramme..
19
21 Feb
CHEMM
Vi sidder her under træet og bliver helt skizofrene. Hvad skete der lige her. Tælleren tog et hop op..
18
19 Feb
FING-B
Så lukkede FPC over den gamle modstand i dag i 19,55 modstanden var 19,47 og næste stop er nu 21,786..
18
15 Feb
VELO
Jeg har solgt mine Veloxis-aktier, for der er nogle mekanismer i stigningerne i både Chemometec og i..
18
18 Feb
VWS
VESTAS LEADS BREAK-AWAY GROUP OF ONSHORE TURBINE MAKERS (fra 16% til 22% af det totale marked for la..
17
18 Feb
PNDORA
Det er netop kommet frem, at tyske BAFIN, svarende til Finanstilsynet i Dk., har forbudt short posit..
17
19 Feb
VELO
Til dem af jer der ikke er med i FB gruppen: Canada havde, sammen med US, lukket i går. Teorien er, ..
16
21 Feb
GEN
Igen i dag ses de Anonyme (ANON) dvs. hovedsageligt shorterne - hen over dagen næsten desperat søger..
15

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

Related news
22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Bavarian Nordic Announces Initiation of Phase 1/2a Clinical Trial of Therapeutic HPV Vaccine Regimen in Collaboration with Janssen
2
Bragar Eagel & Squire, P.C. is Investigating Domino’s Pizza, Inc. (DPZ) on Behalf of Stockholders and Encourages DPZ Investors to Contact the Firm
3
Melinta Therapeutics Announces One-for-Five Reverse Stock Split
4
Odyssey Moon Extends Its Heartfelt Congratulations to SpaceIL for the Successful Launch of the First Non-Governmental Spacecraft to the Moon
5
Bragar Eagel & Squire, P.C. is Investigating Vanda Pharmaceuticals Inc. (VNDA) on Behalf of Stockholders and Encourages VNDA Investors to Contact the Firm

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 February 2019 09:19:41
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB3 - 2019-02-22 10:19:41 - 2019-02-22 09:19:41 - 1000 - Website: OKAY